KR100852479B1 - 혈당강하 효과를 갖는 운지버섯 유래 다당체 및 그 제조방법 - Google Patents
혈당강하 효과를 갖는 운지버섯 유래 다당체 및 그 제조방법 Download PDFInfo
- Publication number
- KR100852479B1 KR100852479B1 KR1020070008510A KR20070008510A KR100852479B1 KR 100852479 B1 KR100852479 B1 KR 100852479B1 KR 1020070008510 A KR1020070008510 A KR 1020070008510A KR 20070008510 A KR20070008510 A KR 20070008510A KR 100852479 B1 KR100852479 B1 KR 100852479B1
- Authority
- KR
- South Korea
- Prior art keywords
- polysaccharide
- mycelium
- fingering
- glucose
- culture
- Prior art date
Links
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 19
- 241000222355 Trametes versicolor Species 0.000 title abstract description 4
- 229920001222 biopolymer Polymers 0.000 title description 5
- 150000004676 glycans Chemical class 0.000 claims abstract description 76
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 76
- 239000005017 polysaccharide Substances 0.000 claims abstract description 76
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 49
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 37
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 28
- 238000009630 liquid culture Methods 0.000 claims abstract description 28
- 239000008103 glucose Substances 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims description 34
- 238000005119 centrifugation Methods 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 229940024606 amino acid Drugs 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 244000061456 Solanum tuberosum Species 0.000 claims description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 26
- 241000700159 Rattus Species 0.000 abstract description 19
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 16
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 16
- 108010003415 Aspartate Aminotransferases Proteins 0.000 abstract description 15
- 102000004625 Aspartate Aminotransferases Human genes 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 abstract description 12
- 235000012000 cholesterol Nutrition 0.000 abstract description 12
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 abstract description 12
- 229960001052 streptozocin Drugs 0.000 abstract description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 7
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 6
- -1 hypoglycemic effect Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 108010022457 polysaccharide peptide Proteins 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920001231 Polysaccharide peptide Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002391 anti-complement effect Effects 0.000 description 2
- 108010008730 anticomplement Proteins 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
그룹 | 경구투여 |
정상군1 ) | 없음 |
대조군2 ) | 0.9 % 생리식염수(NaCl) |
배양여액2 ) | 운지버섯 균사체 액체배양 여액으로부터 얻어진 다당체 |
균사체2 ) | 운지버섯 균사체 액체배양 후 균사체로부터 얻어진 다당체 |
자실체2 ) | 운지버섯 자실체로부터 얻어진 다당체 |
1) 정상 쥐이고 개체수는 9마리이다. 2) 9 마리의 쥐에게 스트렙토조토신(50mg/kg체중)을 투여하여 당뇨쥐를 유도하였다. 대조군과 실험군에는 2주 동안 각각 생리식염수(대조군), 배양여액, 균사체, 자실체 추출물을 체중 kg 당 100mg만큼씩 매일 투여하였다. |
그룹1 ) | 체중증가 (g/day) | 식이섭취 (g/day) | 식이효율2 )(%) |
정상군 | 6.32 ± 0.32c | 25.41 ± 0.80a | 0.24 ± 0.01c |
대조군 | 2.69 ± 0.36a | 39.79 ± 0.61c | 0.07 ± 0.01a |
배양여액 | 3.49 ± 0.22ab | 31.04 ± 0.44ab | 0.11 ± 0.01ab |
균사체 | 3.42 ± 0.15ab | 34.36 ± 0.63ab | 0.11 ± 0.01ab |
자실체 | 3.44 ± 0.28ab | 32.63 ± 0.99ab | 0.10 ± 0.01ab |
1) 표1과 같다. 2) 체중증가/식이섭취. 각각의 값은 9마리의 흰쥐에 대한 평균표준±오차이다. 다른 윗첨자로 되어 있는 a, b, c 값은 p < 0.05에서 동일한 칸에서 다른 군 사이에 유의한 차이가 있다는 것을 나타낸다. |
그룹1 ) | 포도당 (mg/dl) | 총콜레트레롤 (mg/dl) | 트리글라이세라이드(mg/dl) |
정상군 | 154.52± 6.94a | 58.56 ± 5.12a | 45.89 ± 6.40a |
대조군 | 525.96 ± 14.31c | 72.26 ± 3.95b | 101.20± 8.30c |
배양여액 | 417.90 ± 43.24b | 56.52 ± 0.97a | 58.22 ±7.33ab |
균사체 | 463.01 ± 9.12b | 59.95 ± 2.23a | 67.91 ± 6.40b |
자실체 | 469.97 ± 22.38bc | 61.51 ± 3.20a | 70.62 ±7.72ab |
1) 표1과 같다. 각각의 값은 9마리의 흰쥐에 대한 평균표준±오차이다. 다른 윗첨자로 되어 있는 a, b, c 값은 p < 0.05에서 동일한 칸에서 다른 군 사이에 유의한 차이가 있다는 것을 나타낸다. |
그룹1 ) | ALT (IU/L) | AST (IU/L) |
정상군 | 12.38± 0.50a | 72.46 ±8.10a |
대조군 | 73.37 ± 6.50c | 157.00 ± 9.91c |
배양여액 | 33.45 ± 3.54b | 105.52 ± 6.92b |
균사체 | 39.72 ±3.99b | 105.79± 7.91b |
자실체 | 39.21 ±4.11b | 111.67± 9.60b |
1) 표1과 같다. 각각의 값은 9마리의 흰쥐에 대한 평균표준±오차이다. 다른 윗첨자로 되어 있는 a, b, c 값은 p < 0.05에서 동일한 칸에서 다른 군 사이에 유의한 차이가 있다는 것을 나타낸다. |
당 | 조성 (%)1 | 아미노산 | 조성(%)2 |
퓨코우즈 | 8.6 | 아스파르트산 | 7.3 |
리보오스 | 0.2 | 트레오닌 | 7.0 |
아라비노우즈 | 0.5 | 세린 | 8.9 |
자일로우즈 | 1.7 | 글루탐산 | 7.2 |
만노우즈 | 39.2 | 글리신 | 2.4 |
갈락토우즈 | 15.4 | 알라닌 | 13.1 |
글루코우즈 | 34.4 | 시스테인 | 3.4 |
발린 | 8.0 | ||
이소루이신 | 14.7 | ||
루이신 | 5.3 | ||
티로신 | 3.1 | ||
페닐알라닌 | 5.3 | ||
히스티딘 | Trace | ||
라이신 | 2.8 | ||
아르기닌 | 2.1 | ||
총 당 함량 | 60.93 | 총 아미노산 함량 | 28.58 |
1 퍼센트는 총당당 함량으로 계산하였다. 2 퍼센트는 총 아미노산당 함량으로 계산하였다. |
Claims (3)
- 운지버섯을 감자/덱스트로우즈 아가 배지(pH 5)에 접종하고 4℃에서 보관하며 석 달마다 계대배양하는 단계;상기 배양균을 감자/덱스트로우즈 브로스(pH 5)에 넣고 25℃의 회전식진탕기(120 rpm)에서 종균배양하는 단계;상기 배양 4일 후, 상기 배양액을 무균상태에서 분쇄하고나서 상기 분쇄물을 미리 제조한 배양배지(글루코우즈 20 g/L, MgSO4 · 7H2O 0.5 g/L, K2HPO4 1 g/L, KH2PO4 0.46 g/L, 효모 추출물 2 g/L, 펩톤 2 g/L 멸균하기 전에 pH는 5로 조정함)에 2%(v/v)으로 접종하는 단계;상기 분쇄물을 포함한 배양액을 150 rpm, 25℃ 조건의 회전식진탕기에서 10일 동안 균사체 액체 배양하는 단계;상기 균사체 액체배양 여액을 10,447 x g로 20분간 원심분리하여 얻은 상등액을 에탄올 침전시켜 4℃에 24시간 방치 후 원심분리하는 단계; 및상기 원심분리로 얻은 침전물을 물로 희석 및 투석한 다음 동결건조하여 다당체를 얻는 단계로 이루어진 것을 특징으로 하는, 운지버섯 균사체 액체배양 여액에서 다당체의 제조 방법.
- 제1항의 방법으로 제조된, 60.9%의 탄수화물과 28.5%의 단백질을 포함하고, 주 구성당인 만노우즈, 글루코우즈 및 갈락토우즈의 함량 비율은 각각 39.2%, 34.2% 및 15.4%이고 , 주 구성 아미노산인 이소루신, 알라닌 및 세린의 함량 비율은 각각 14.7%, 13.1% 및 8.9%인 것을 특징으로 하는 혈당강하 활성이 있는 운지버섯 균사체 액체배양 여액 유래의 다당체.
- 제1항의 방법으로 제조된 운지버섯 균사체 액체배양 여액 유래의 다당체를 유효성분으로 함유하는 것을 특징으로 하는 당뇨병 치료용 및 예방용 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070008510A KR100852479B1 (ko) | 2007-01-26 | 2007-01-26 | 혈당강하 효과를 갖는 운지버섯 유래 다당체 및 그 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070008510A KR100852479B1 (ko) | 2007-01-26 | 2007-01-26 | 혈당강하 효과를 갖는 운지버섯 유래 다당체 및 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080070416A KR20080070416A (ko) | 2008-07-30 |
KR100852479B1 true KR100852479B1 (ko) | 2008-08-18 |
Family
ID=39823173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070008510A KR100852479B1 (ko) | 2007-01-26 | 2007-01-26 | 혈당강하 효과를 갖는 운지버섯 유래 다당체 및 그 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100852479B1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008243A (en) | 1983-08-11 | 1991-04-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition containing a glycoprotein |
KR20060114132A (ko) * | 2005-04-27 | 2006-11-06 | 박미연 | 버섯 균사체의 배양방법 |
KR20070018337A (ko) * | 2005-08-09 | 2007-02-14 | 영동 기능식품 주식회사 | 운지버섯 균사체 생산 방법, 이로부터 제조된 운지버섯균사체 및 이를 함유하는 건강기능식품 |
-
2007
- 2007-01-26 KR KR1020070008510A patent/KR100852479B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008243A (en) | 1983-08-11 | 1991-04-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition containing a glycoprotein |
KR20060114132A (ko) * | 2005-04-27 | 2006-11-06 | 박미연 | 버섯 균사체의 배양방법 |
KR20070018337A (ko) * | 2005-08-09 | 2007-02-14 | 영동 기능식품 주식회사 | 운지버섯 균사체 생산 방법, 이로부터 제조된 운지버섯균사체 및 이를 함유하는 건강기능식품 |
Also Published As
Publication number | Publication date |
---|---|
KR20080070416A (ko) | 2008-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Hypoglycemic effect of a Lentinus edodes exo-polymer producedfrom a submerged mycelial culture | |
Wang et al. | Optimization for the production of water-soluble polysaccharide from Pleurotus citrinopileatus in submerged culture and its antitumor effect | |
KR101031605B1 (ko) | 당뇨병 질환의 예방 및 치료를 위한 세리포리아 락세라타 배양액 추출물의 제조방법 및 이에 따른 세리포리아 락세라타 배양액 추출물 | |
US20020164773A1 (en) | Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom | |
US20020137155A1 (en) | Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher Basidiomycetes mushroom | |
JP5658479B2 (ja) | 脂肪減少等の活性を示す組成物 | |
Yang et al. | Hypoglycemic effects of Ganoderma applanatum and Collybia confluens exo‐polymers in streptozotocin‐induced diabetic rats | |
KR100663712B1 (ko) | 상황버섯의 균사체로부터 얻은 항당뇨 활성이 있는세포외다당체 및 그 제조방법 | |
JPS6234396B2 (ko) | ||
Oluba et al. | Evaluation of the hypoglycemic effect of aqueous extract of Ganoderma lucidum on STZ-induced diabetic wistar rats | |
JPH01228480A (ja) | 食用担子菌菌糸体培養抽出物の製造方法 | |
Yang et al. | Hypoglycemic effects of exo-biopolymers produced by five different medicinal mushrooms in STZ-induced diabetic rats | |
CN111253496B (zh) | 一种具有降血糖功效的亮菌菌丝体多糖 | |
Yang et al. | Antidiabetic and hypolipidemic effects of Collybia confluens mycelia produced by submerged culture in streptozotocin-diabetic rats | |
KR100852479B1 (ko) | 혈당강하 효과를 갖는 운지버섯 유래 다당체 및 그 제조방법 | |
KR100936176B1 (ko) | 붉은덕다리버섯(Leatiporussulphureus var. miniatus) 균사체배양액 유래의 항당뇨 활성을 갖는 세포외다당체 및 그제조방법 | |
JP2002087981A (ja) | 糖質脂質代謝異常改善剤 | |
KR20080079962A (ko) | 흰목이 버섯 균사체 유래의 항당뇨 활성 세포외다당체 및그 제조방법 | |
KR102380296B1 (ko) | 기계충버섯(Irpex lacteus) 균사체 배양물 및 이를 유효성분으로 포함하는 당뇨병 예방 및 치료용 조성물 | |
KR100963511B1 (ko) | 제2형 당뇨치료 효과가 있는 상황 버섯 균사체 유래의항당뇨 활성 세포외다당체 및 그 제조방법 | |
JP2002114701A (ja) | 脂質代謝改善組成物 | |
KR20050014237A (ko) | 각종 버섯 액체배양물을 함유한 기능성 소주 및 그 제조방법 | |
KR20050078860A (ko) | 각종 버섯의 자실체 또는 균사체로부터 얻은 추출물들을함유한 기능성 소주 및 그 제조방법 | |
KR100475444B1 (ko) | 균사체 액체배양에 의해 생산된 표고버섯유래세포외다당체의 당뇨병 치료용 조성물 및 그 분리방법 | |
KR100780664B1 (ko) | 저지혈증 효과를 갖는 목이버섯 자실체 유래의 다당체 및그 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120803 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130726 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140811 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150807 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160809 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170804 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180821 Year of fee payment: 11 |